A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)
209664
Phase 1 other active
Quick answer
A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9) for Multiple Myeloma is a Phase 1 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Multiple Myeloma
- Phase
- Phase 1
- Modality
- other
- Status
- active